Seaport Therapeutics Reports Q1 2026 Results, $260M IPO Proceeds
Seaport Therapeutics reported Q1 2026 financial results and announced new Phase 1 data for GlyphAgo showing therapeutic exposures without liver enzyme elevation concerns. The company's recent upsized IPO generated $260M in gross proceeds, providing funding runway into 2029 while
View filing at SEC.gov →